The Cerebrotendinous Xanthomatosis Therapy Market is driven by Increasing Incidences of Inherited Genetic Disorders
The global cerebrotendinous xanthomatosis therapy market is primarily driven by increasing incidences of inherited genetic disorders worldwide. Cerebrotendinous xanthomatosis is a rare, inherited disorder that affects many systems in the body. People with this condition cannot properly break down a fatty compound called cholesterol in their body. As a result, excess cholesterol and a waxy substance called cholestanol build up in various tissues and organs. This buildup causes characteristic xanthomas (yellowish fatty deposits) in tendons and tissues near the eyelids. It can also cause neurological problems such as spastic movements, intention tremor, psychiatric symptoms, seizures and intellectual disability if left untreated. The symptoms often begin in the second or third decade of life and progress slowly.
The cerebrotendinous xanthomatosis market is estimated to be valued at USD 167.3 Mn in 2024 and is expected to reach USD 359.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031.
Therapeutics to treat neurological abnormalities, psychiatric symptoms, movement disorders and vision problems associated with cerebrotendinous xanthomatosis are in high demand.
Key Takeaways
Key players operating in the cerebrotendinous xanthomatosis therapy market are Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Idorsia Pharmaceuticals Ltd., Intravel Pharmaceuticals.
Growing incidences of genetic inherited disorders and increasing awareness about early diagnosis and treatment are fueling the demand for Cerebrotendinous Xanthomatosis Market therapeutics globally.
Leading manufacturers are expanding their presence in developing markets of Asia Pacific and Latin America to tap the high growth opportunities in these regions.
Market Drivers
Increasing research funding for rare diseases is positively impacting the cerebrotendinous xanthomatosis therapy market. Government organizations as well as private foundations worldwide are offering significant grants to expedite research & development of new therapeutics for cerebrotendinous xanthomatosis and related genetic disorders. This is encouraging pharmaceutical companies to develop novel treatment options for this rare health condition.
Get more insights on – Cerebrotendinous Xanthomatosis Market
Get this Report in Japanese Language: 脳腱黄色腫症市場
Get this Report in Korean Language: 뇌건황색종증 시장
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian